



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Jonathan M. J. Derry, William C. Fanslow
III, and William C. Dougall

Docket No.: 3198

Group Art Unit: 1645

Serial No: 09/851,673

Examiner: Unknown

Filed: May 8, 2001

For: SCREENING ASSAYS FOR AGONISTS OR ANTAGONISTS OF CD40
SIGNALING

INFORMATION DISCLOSURE STATEMENT

BOX NON FEE

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, Applicants hereby disclose publications known to them which may be material to the patentability of this invention. The publications are listed on the attached Form PTO-1449. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

Since the submission of the documents listed on the Form PTO-1449 is made before the mailing of a first Office Action on the merits, no filing fee is believed to be required. However, should it be determined that a fee is necessary, Applicants authorize the Commissioner to charge Applicants' deposit account no. 09-0089 in an amount necessary to permit consideration of this Information Disclosure Statement.

Respectfully submitted,

Patricia Anne Perkins
Registration No. 34,693

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone: (206) 587-0430

1645
#5
#5 Plunkett
5/8/02
RECEIVED
AUG 01 2001
TECH CENTER 1600/2900